264 related articles for article (PubMed ID: 9439546)
1. Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
Metabolism; 1997 Dec; 46(12):1473-6. PubMed ID: 9439546
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
4. Effects of allopurinol on beer-induced increases in plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine).
Ka T; Moriwaki Y; Inokuchi T; Yamamoto A; Takahashi S; Tsutsumi Z; Yamamoto T
Horm Metab Res; 2006 Mar; 38(3):188-92. PubMed ID: 16673211
[TBL] [Abstract][Full Text] [Related]
5. Influence of urate-lowering therapies on renal handling of uric acid.
Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Wu J; Zhang YP; Qu Y; Jie LG; Deng JX; Yu QH
Int J Rheum Dis; 2019 Aug; 22(8):1445-1451. PubMed ID: 31317680
[TBL] [Abstract][Full Text] [Related]
7. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
Mertz DP; Eichhorn R
Klin Wochenschr; 1984 Dec; 62(24):1170-2. PubMed ID: 6530890
[TBL] [Abstract][Full Text] [Related]
8. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
9. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
Müller FO; Schall R; Groenewoud G; Hundt HK; van der Merwe JC; van Dyk M
Eur J Clin Pharmacol; 1993; 44(1):69-72. PubMed ID: 8436158
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
11. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
[TBL] [Abstract][Full Text] [Related]
12. [The influence of allopurinol on purine- and pyrimidinesynthesis (author's transl)].
Gröbner W; Zöllner N
Klin Wochenschr; 1978 Mar; 53(16):255-60. PubMed ID: 682520
[TBL] [Abstract][Full Text] [Related]
13. The pharmacology of hypouricemic effect of benzbromarone.
Sinclair DS; Fox IH
J Rheumatol; 1975 Dec; 2(4):437-45. PubMed ID: 1206675
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise.
Kaya M; Moriwaki Y; Ka T; Inokuchi T; Yamamoto A; Takahashi S; Tsutsumi Z; Tsuzita J; Oku Y; Yamamoto T
Metabolism; 2006 Jan; 55(1):103-7. PubMed ID: 16324927
[TBL] [Abstract][Full Text] [Related]
15. Gout due to xanthine derivatives.
Toda K; Goriki K; Ochiai M; Tokunou H; Uehara S; Takahashi H; Okusaki K
Br J Rheumatol; 1997 Oct; 36(10):1131-2. PubMed ID: 9374937
[No Abstract] [Full Text] [Related]
16. Excellent response to the clinical treatment of tophaceous gout.
Caldas CA; Fuller R
Clin Rheumatol; 2007 Sep; 26(9):1553-5. PubMed ID: 17047891
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
Stocker SL; Graham GG; McLachlan AJ; Williams KM; Day RO
J Rheumatol; 2011 May; 38(5):904-10. PubMed ID: 21285173
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
[TBL] [Abstract][Full Text] [Related]
19. Effects of allopurinol on beer-induced increases in plasma concentrations of purine bases and uridine.
Inokuchi T; Ka T; Yamamoto A; Takahashi S; Tsutsumi Z; Moriwaki Y; Yamamoto T
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):601-3. PubMed ID: 18600512
[TBL] [Abstract][Full Text] [Related]
20. [Hyperuricemia and gout--treatment].
Gröbner W; Walter-Sack I
Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
